Biotech News
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
ir.tarsusrx.com2026-05-06 14:59 EST
Delivered quarterly XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial momentum Management to host conference call today, November 4, 2025 , at 1:30 p.m.